Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

Rhea-AI Summary

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the presentation of two abstracts on neratinib at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7, 2022, in Chicago, Illinois. The abstracts focus on targeting HER2 mutation-positive advanced biliary tract cancers and the combination therapy of neratinib for hormone receptor-positive, HER2-negative metastatic breast cancer. Full details of the abstracts are accessible on the ASCO website and will be available on Puma's site post-presentation.

Positive

• Presentation of two significant abstracts at ASCO, highlighting ongoing research and development of neratinib.
• Continued focus on innovative cancer therapies, indicating strong R&D commitment.

Negative

• None.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 3 - 7, 2022. The corresponding abstracts of the two posters that Puma will be presenting are now live on the 2022 ASCO Annual Meeting website. The full posters will be available on the Puma website following the presentations.

Full abstracts of the following posters are available online at: ASCO.org/abstracts.

Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

• Abstract 4079: Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT ‘basket’ trial
  JJ Harding, S Piha-Paul, RH Shah, JM Cleary, D Quinn, I Braña, V Moreno, M Borad, S Loi, I Spanggaard, J Ford, D DiPrimeo, MF Berger, LD Eli, F Meric-Bernstam, DB Solit, GK Abou-Alfa
  Presenter: James J. Harding, MD | Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
  Date/Time: June 4, 2022, at 9:00 am ET

Poster Session: Breast Cancer—Metastatic

• Abstract 1028: Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
  K Jhaveri, JW Goldman, SA Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, ES Yang, I Spanggaard, S Reid, M Burkard, A Prat, S Loi, J Crown, A Hanker, C Ma, R Bose, LD Eli, H Wildiers
  Presenter: Komal L. Jhaveri, FACP, MD | Memorial Sloan Kettering Cancer Center
  Date/Time: June 6, 2022, at 9:00 am ET

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005637/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

What abstracts is Puma Biotechnology presenting at ASCO 2022?

Puma Biotechnology is presenting two abstracts on neratinib, focusing on advanced biliary tract cancers and hormone receptor-positive metastatic breast cancer.

When is the ASCO 2022 Annual Meeting?

The ASCO 2022 Annual Meeting will take place from June 3 to June 7, 2022.

What is neratinib and its significance?

Neratinib is an oral medication approved for the treatment of certain types of breast cancer and advanced biliary tract cancers, showcasing Puma's innovative approach in oncology.

Where can I find the full abstracts presented by Puma Biotechnology?

The full abstracts are available on the ASCO website and will also be published on Puma's official website after the presentations.